Revance Therapeutics, Inc. Overview
Pro stress-test →Revance Therapeutics is a biotechnology company that develops and commercializes neuromodulators for aesthetic and therapeutic indications. The company was acquired by Crown Laboratories in February 2025, transitioning from public to private ownership. DAXXIFY (daxibotulinumtoxinA-lanm), its core product, is the fastest-growing neurotoxin in the U.S., reaching one million vials distributed by September 2025.
Strategic Profile
Pro stress-test →Revance's strategy focuses on capturing market share from incumbents like Allergan's Botox by offering a differentiated product profile in a market projected to reach $8 billion. As a Crown subsidiary, the business concentrates on core aesthetic and therapeutic product lines including DAXXIFY and the RHA Collection of dermal fillers. The company operates internationally through partnerships with Teoxane SA in Switzerland and Shanghai Fosun Pharmaceutical in China for product commercialization.
Competitive Landscape
Pro stress-test →Revance competes directly with Allergan's BOTOX in the botulinum toxin market, differentiating through longer duration and improved movement profiles. Key competitors include established players in neuromodulators and dermal fillers. Revance's proprietary peptide technology and rapid commercialization of DAXXIFY position it as a disruptor in the $8 billion aesthetic injectables market.
Industry Context
Revance Therapeutics, Inc. operates in Pharmaceutical Aesthetics & Therapeutic Injectables.
Key facts
Founded: 1999 · Headquarters: Nashville, US · Employees: 597 · Revenue: $256.95M